DARREL FOISTER: Open Payments
NPI 1942047196 · WASILLA, AK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,104 in 47 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $272 · 2025 $1,104
Food & beverage: $1,104
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $225 |
| ABBVIE INC. | 5 | $201 |
| GlaxoSmithKline, LLC. | 13 | $137 |
| Gilead Sciences, Inc. | 1 | $95 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $74 |
| Amgen Inc. | 3 | $55 |
| Lilly USA, LLC | 2 | $38 |
| Novartis Pharmaceuticals Corporation | 2 | $37 |
| Novo Nordisk Inc | 2 | $34 |
| TMS NeuroHealth Centers Inc. | 1 | $33 |
Products named: AIRSUPRA, QULIPTA, Veklury, TRELEGY ELLIPTA, XIFAXAN, SHINGRIX, MOUNJARO, FARXIGA.
Industry payments across AK — which companies pay providers there.
